Pediatric clinical trials are the only criteria for
launching new drugs in the market for various indications that affect the
paediatric population, and as a result, the pharmaceutical and biotechnological
industries have been gradually shifting from in-house clinical research to
contract research organisations (CRO).
Due to unmet medical needs in the paediatric patient
population, there is a considerable product pipeline in the clinical stage of
development. In the foreseeable future, a robust medication development
pipeline will provide lucrative growth prospects for the industry. According to
2018 data from the Pharmaceutical Research and Manufacturers Association
(PHRMA). Furthermore, by 2020, nearly 1,300 industry-sponsored paediatric
clinical studies will be underway across a wide range of therapeutic
categories, including infectious diseases, neurologic problems, genetic
abnormalities, and numerous types of cancer.
In the global market, North America is expected to hold the
largest share
The pediatric
clinical trial market is dominated by North America, which is projected
to continue in this pattern over the forecast period. In the North American
area, the United States is the largest market.
The United States is predicted to have a sizable proportion
of the market, with a similar trend expected during the projection period.
According to clinicaltrials.gov, there were over 1,265 active paediatric
clinical trials in the United States as of June 2021, accounting for a
significant fraction of the global number of paediatric research operations. In
the United States, the high number of studies and high cost per procedure and
patient have had a significant impact on the industry. The rising frequency of
disorders among the country's juvenile population is fueling research
initiatives to produce particular medications, resulting in an increase in the
number of clinical trials in the country. According to the National Diabetes
Statistics Report 2020, an estimated 187,000 children and adolescents in the
United States were diagnosed with Type 1 diabetes in 2018, and this figure is
expected to rise in the coming years.
Comments
Post a Comment